✦ LIBER ✦

Phase II studies of 4′-iodo-4′-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers

Book ID: 122004774
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 157 KB
Volume: 8
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(92)90194-O

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of 4′-iodo-4′-deoxydoxoru

Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

✍ Jens Benn Sørensen; Lars Stenbygaard; Lars Drivsholm; Per Dombernowsky; Heine H. 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 401 KB

Phase II study of 4′-iodo-4′-deoxydoxoru

Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 297 KB

Phase II study of 4′-iodo-4′-deoxydoxoru

Phase II study of 4′-iodo-4′-deoxydoxorubicin in patients with advanced, measurable non-small cell lung cancer

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 148 KB

A phase II study of 4-deoxydoxorubicin i

A phase II study of 4-deoxydoxorubicin in advanced breast cancer

✍ Knight, Robert K.; Rubens, Robert D.; Rankin, Elaine M. 📂 Article 📅 1987 🏛 Elsevier Science ⚖ 732 KB

Phase II trial of esorubicin (4′ deoxydo

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

✍ Theodore A. Braich; Sydney E. Salmon; Aurelia Robertone; David S. Alberts; Steph 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 410 KB

Phase II trial of esorubicin (4′deoxydox

Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer

✍ James R. Rigas; Mark G. Kris; Richard J. Gralla; Robert T. Heelan; Linda D. Mark 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 264 KB

Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m 2 intravenously) every 3 we